CASI Pharmaceuticals IncNASDAQ:CASI
- LAST PRICE2.8500
- TODAY'S CHANGE (%)-0.2500 (-8.0645%)
- Bid / Lots2.8000/ 1
- Ask / Lots3.1800/ 3
- Open / Previous Close3.1900 / 3.1000
- Day Range
- 52 Week Range
- Volume28,111
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CASI |
|---|---|---|
| 09:32 ET | 880 | 3.19 |
| 09:36 ET | 100 | 3.15 |
| 09:39 ET | 100 | 3.12 |
| 09:41 ET | 680 | 3.12 |
| 09:57 ET | 1257 | 3.15 |
| 10:39 ET | 193 | 3.1499 |
| 10:42 ET | 1900 | 3.15 |
| 10:46 ET | 100 | 3.15 |
| 11:02 ET | 1337 | 3.1 |
| 11:06 ET | 500 | 3.05 |
| 11:58 ET | 1149 | 3 |
| 12:07 ET | 100 | 3.05 |
| 12:54 ET | 185 | 3 |
| 01:12 ET | 100 | 3.005 |
| 01:17 ET | 1000 | 2.9701 |
| 01:19 ET | 1100 | 2.97 |
| 01:39 ET | 362 | 2.97 |
| 02:04 ET | 662 | 2.91 |
| 02:13 ET | 5643 | 2.91 |
| 02:22 ET | 100 | 2.9 |
| 02:44 ET | 500 | 2.9599 |
| 03:03 ET | 100 | 2.98 |
| 03:23 ET | 2625 | 2.91 |
| 03:27 ET | 2281 | 2.91 |
| 03:30 ET | 1314 | 2.93 |
| 03:32 ET | 100 | 2.92 |
| 03:54 ET | 200 | 2.88 |
| 03:56 ET | 175 | 2.87 |
| 03:57 ET | 100 | 2.79 |
| 03:59 ET | 300 | 2.85 |
May 17, 2023
BRIEF-Casi Pharmaceuticals Announces First Quarter 2023 Financial Results, from 7:37AM ET on Wednesday May 17, 2023 by Thomson Reuters
7:37AM ET on Wednesday May 17, 2023 by Thomson Reuters-- Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q1 Revenue $8.3M, from 7:36AM ET on Wednesday May 17, 2023 by MT Newswires
7:36AM ET on Wednesday May 17, 2023 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CASI Pharmaceuticals Inc | 38.0M | -1.0x | --- |
MEI Pharma Inc | 50.0M | -1.3x | --- |
Janone Inc | 4.1M | -0.9x | --- |
MDxHealth SA | 63.1M | -1.5x | --- |
Harpoon Therapeutics Inc | 30.1M | -0.5x | --- |
Champions Oncology Inc | 71.0M | -22.7x | --- |
Company Information
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products. The Company's product EVOMELA is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. The Company’s pipeline includes CNCT19, BI-1206, CB-5339, CID-103, Octreotide, and Thiotepa. CNCT19 is used for the treatment of patients with hematological malignancies which express CD19 including, B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). CB-5339 is a Valosin-containing protein (VCP/p97) inhibitor focused on VCP/p97 as a target in protein homeostasis, deoxyribonucleic acid (DNA) damage response, and other cellular stress pathways for use in the treatment of patients with various malignancies. Thiotepa is a chemotherapeutic agent used prior to certain allogeneic hemopoietic stem cell transplants.
Contact Information
- Headquarters
- 9620 Medical Center Dr Ste 300ROCKVILLE, MD, United States 20850-3396
- Phone
- 240-864-2600
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Wei-wu He
- President, Principal Financial Officer
- Wei Zhang
- Chief Operating Officer
- Chunhua Wang
- Executive Vice President, Chief Medical Officer
- Alexander Zukiwski
- Vice President, Controller
- Kun Qian
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $38.0M |
|---|---|
Revenue (TTM) | $42.4M |
Shares Outstanding | 13.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.45 |
EPS | $-2.84 |
Book Value | $3.31 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | 0.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -80.10% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
